Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models
Peritoneale Chemotherapiesysteme zur Behandlung von Ovarialkarzinom: systematische Übersicht von Tiermodellen
Frontiers in Oncology · 08.01.2025 · 14
DOI: 10.3389/fonc.2024.1487376 ↗Auf einen Blick
Die Übersichtsarbeit fand in Tiermodellen einen kleinen Vorteil von Drug-Delivery-Systemen gegenüber freier intraperitonealer Chemotherapie bei Tumorgröße und -gewicht. Beim Tiergewicht zeigte sich kein Unterschied.
Fragestellung
Vergleich von Tumoransprechen und Toxizität zwischen intraperitonealer Chemotherapie über Drug-Delivery-Systeme und freier intraperitonealer Chemotherapie in Tiermodellen des Ovarialkarzinoms.
Methode
Systematische Übersichtsarbeit nach PRISMA und SYRCLE; 38 Studien identifiziert, 20 in der Metaanalyse; Auswertung von Tumorvolumen, Tumorgewicht und Tiergewicht.
Ergebnisse
20 Studien in der Metaanalyse. Tumorgewicht: SMD -1,06 (95 %-KI -1,34 bis -0,78). Tumorvolumen: SMD -3,72 (95 %-KI -4,47 bis -2,97). Kein Gewichtsverlust der Tiere.
Einschränkungen
In einigen Vergleichen wurde eine signifikante Heterogenität beobachtet.
Schlussfolgerung der Autor:innen
Slow-Release-Systeme sind in Tiermodellen insgesamt sicher und wirksam. Welches System am vielversprechendsten ist, ließ sich wegen der vielen verschiedenen Systeme nicht beurteilen.
Kernaussagen
- Tumorgewicht und -volumen waren unter DDS geringer als unter freier Gabe
- Kein Gewichtsverlust der Tiere unter DDS
- Verschiedene DDS-Typen verhinderten einen Vergleich des besten Systems
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 08.01.2025. Verfasst von Marcelo Simonsen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Radiologia e Oncologia, Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Intraperitoneal chemotherapy for ovarian cancer treatment has controversial benefits as most methodologies are associated with significant morbidity. We carried out a systematic review to compare tumor response, measured by tumor weight and volume, between intraperitoneal chemotherapy delivered via drug delivery systems (DDSs) and free intraperitoneal chemotherapy in animal models of ovarian cancer. The secondary aim was to assess the toxicity of DDS-delivered chemotherapy, based on changes in animal body weight.
Methods
Based on PRISMA and SYRCLE guidelines, we identified 38 studies for review, of which 20, were used in the meta-analysis. We evaluated outcome, through tumor volume and tumor weight and, toxicity, through animal weight. Analysis was based on drugs employed and treatment duration.
Results
Most studies were performed on mice. Ovarian cancer cell lines most commonly used to induce xenografts were SKOV3 (19 studies) and A2780 (6 studies). Intraperitoneal device, also known as drug delivery systems (DDS), consisted in nanoparticles, hydrogels, lipid polymer and others. The most commonly used drugs were paclitaxel and cisplatin. Most studies used as the control treatment the same chemotherapy applied free intraperitoneally and tumor response/animal weight were evaluated weekly. There was a small benefit in overall tumor reduction in animals treated with intraperitoneal chemotherapy applied through the slow release device compared with animals treated with intraperitoneal free chemotherapy, as evaluated through tumor weight - results in standardized mean difference. (-1.06; 95% CI: -1.34, -0.78) and tumor volume (-3.72; 95% CI: -4.47, -2.97), a benefit that was seen in most weekly evaluations and for most chemotherapy drugs, such as carboplatin (tumor weight: -5.60; 95% CI: -7.83, -3.37), paclitaxel (tumor weight: -1.18; 95% CI: -1.52, -0.83), and cisplatin (tumor volume: -2.85; 95% CI: -3.66, -2.04) carboplatin (tumor volume: -12.71; 95% CI: -17.35, -8.07); cisplatin (tumor volume: -7.76; 95% CI: -9.88, -5.65); paclitaxel (tumor volume: -2.85; 95% CI: -3.66, -2.04). Regarding animal weight, there was no weight reduction in animals treated with intraperitoneal chemotherapy applied through the slow-release device compared with animals treated with intraperitoneal free chemotherapy. However, significant heterogeneity was observed in some comparisons. Conclusion slow-release devices are overall safe and effective in animal models of ovarian cancer. It was not possible to evaluate which one is the most promising device to treat ovarian cancer, because many different types were used to apply chemotherapy intraperitoneally. Systematic Review Registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42021224573.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Radiologia e Oncologia, Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (HCFMUSP), Sao Paulo, SP, Brazil.
- Gynecology and Obstetrics Department, Instituto de Assistência Médica ao Servidor Público Estadual (IAMSPE), São Paulo, SP, Brazil.
- Departamento de Radiologia e Oncologia, Comprehensive Center for Precision Oncology (C2PO), Centro de Investigação Translacional em Oncologia (CTO), Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Fac…
- Faculdade de Medicina, Undergraduate program, Universidade de Sao Paulo (FMUSP), Sao Paulo, SP, Brazil.
- Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (HCFMUSP), Sao Paulo, SP, Brazil.
- Nuclear and Energy Research Institute, IPEN-Comissão Nacional de Energia Nuclear (CNEN)/SP-University of São Paulo, São Paulo, SP, Brazil.
Zitieren
APA
Simonsen, M., Mendoza López, R. V., Maistro, S., Ikeoka, L. T., Pereira, G. F. L., Lugão, A. B., Sadalla, J. C., Katayama, M. L. H., & Folgueira, M. A. A. K. (2025). Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1487376
Vancouver
Simonsen M, Mendoza López RV, Maistro S, Ikeoka LT, Pereira GFL, Lugão AB, et al. Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models. Frontiers in Oncology. 2025;14. doi:10.3389/fonc.2024.1487376
BibTeX
@article{Simonsen2025,
author = {Simonsen, Marcelo and Mendoza López, Rossana Verónica and Maistro, Simone and Ikeoka, Lucas Takeshi and Pereira, Glaucia Fernanda de Lima and Lugão, Ademar Benévolo and Sadalla, José Carlos and Katayama, Maria Lúcia Hirata and Folgueira, Maria Aparecida Azevedo Koike},
title = {Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models},
journal = {Frontiers in Oncology},
year = {2025},
volume = {14},
doi = {10.3389/fonc.2024.1487376}
}
EUVIMED